Treatment of childhood acute myelogenous leukemia with allogeneic and autologous stem cell transplantation during the first remission: A report from the Kyushu-Yamaguchi children's cancer study group in Japan

Pediatric Hematology and Oncology

Volumn 17, Issue 8, 2000, Pages 623-634

  Matsuzaki, Akinobu ^a   Eguchi, Haruhiko ^b   Ikuno, Yoshiko ^c   Ayukawa, Hiroshi ^d   Yanai, Fumio ^e   Ishii, Eiichi ^f  

^a KYUSHU UNIVERSITY   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d YAMAGUCHI UNIVERSITY   (Japan)

^e FUKUOKA UNIVERSITY   (Japan)

^f HAMANOMACHI HOSPITAL   (Japan)

Author keywords

Acute myelogenous leukemia; Bone marrow transplantation; Childhood; Peripheral blood stem cell

Indexed keywords

BUSULFAN; CYTARABINE; ETOPOSIDE; HYDROCORTISONE; MELPHALAN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; DOWN SYNDROME; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0033661580     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010050211330     Document Type: Article

References (25)

1. Therapy of childhood acute myelogenous leukemia
2. Diagnosis and treatment of childhood acute myelogenous leukemia
3. Acute myelogenous leukemia
4. Autologous bone marrow transplantation for acute myeloid leukemia in children using total body irradiation and melphalan as conditioning regimen
5. Results of intensive therapy in childhood acute myeloid leukemia incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission
6. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: A Childrens Cancer Group Pilot Study
7. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia
8. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood
9. Treatment of high-risk acute lymphoblastic leukemia in children using AL851 and ALHR88 protocols: A report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan
10. Treatment of standard-risk acute lymphoblastic leukemia in children: The results of protocol AL841 from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan
11. Treatment results of acute nonlymphocytic leukemia in childhood
12. Prospective comparison between postinduction chemotherapy and various types of stem-cell transplantation for childhood acute myeloid leukemia using Japan cooperative protocol ANLL91
13. Mitoxantrone-countering regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: Results of the EORTC children leukemia cooperative study 58872
14. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: Results of the United Kingdom Medical Research Council's 10th AML trial
15. Improvement in outcome for children receiving allogeneic bone marrow transplantation in first remission of acute myeloid leukemia: A report from the Groupe d'Etude des Greffes de Moelle Osseuse
16. Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission
17. High-lights of ANLL therapy in Spain
18. Blood stem cell transplants in acute leukemia
19. The source of stem cell does not affect the outcome of patients undergoing autologous stem cell transplantation for acute myeloid leukemia in first remission
20. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen
21. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity
22. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis and alopecia with busultan versus total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia
23. Long-term survivors, an overview on late effects, sequelae and second neoplasias
24. Ovarian function after autologous bone marrow transplantation in childhood: High-dose busulfan is a major cause of ovarian failure
25. Definition of a standard-risk group in children with AML